We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanogen and the French Diagnostic Company Elitech Merge

By LabMedica International staff writers
Posted on 17 Nov 2008
The Elitech Group (Puteaux, France), a private French diagnostic company, announced an agreement to merge with the US company Nanogen, Inc. More...
(San Diego, CA, USA), a developer of molecular and rapid in-vitro diagnostic products. The name of the combined company has not yet been announced.

The combination of the two companies will create a global provider of products to the molecular, point-of-care, clinical chemistry, and microbiology diagnostic markets with expected first year revenues greater than US$150 million.

The transaction combines the strong revenue and profit base stemming from the Elitech Group's global manufacturing, sales, and distribution of in vitro diagnostic (IVD) products for the clinical chemistry and microbiology markets, with Nanogen's technology leadership in molecular and point-of-care diagnostics. The combined business is currently growing at more than 20% annually, and the combined company will benefit from opportunities for even larger revenue growth, especially in molecular biology, rapid tests, clinical chemistry, and microbiology.

Pierre Debiais will lead the new company as its CEO. "This is a true example of synergy between two companies in the in vitro diagnostics industry,” he commented. "We are delighted to be able to combine Nanogen's technology strength with our market reach in the international marketplace and collectively deliver the critical mass required to address the US diagnostic market.”

The share exchange agreement is subject to approval by Nanogen's stockholders as well as customary closing conditions and regulatory approvals. The transaction is expected to close by the end first quarter of 2009.

The Elitech Group is a high growth, profitable IVD company with global sales and distribution capabilities in more than 100 countries. The company is the largest independent distributor of in vitro diagnostic products in France. Elitech offers clinical chemistry, microbiology, immunology, and electrophoresis products.

Nanogen provides diagnostic products to clinicians, physicians, and researchers worldwide, making it easier to predict, diagnose, and treat disease. The company's products include molecular diagnostic kits, reagents, and kits for rapid, point-of-care diagnostic tests.

Related Links:
Elitech Group
Nanogen


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.